1. Yu E, Sharma S. 2020. Cystic
fibrosis. Statpearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2020, StatPearls Publishing LLC.
2. Rosenfeld M, Gibson RL, McNamara S,
Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A et
al. 2001. Early pulmonary infection, inflammation, and clinical outcomes
in infants with cystic fibrosis. Pediatr Pulmonol. 32(5):356-366.
3. Zolin A OA, Naehrlich L, Jung A,
van Rens J et al. 2020. Ecfspr annual report 2018.
4. Cystic fibrosis foundation patient
registry, 2018 annual data report, bethesda, maryland.
5. Emerson J, Rosenfeld M, McNamara S,
Ramsey B, Gibson RL. 2002. Pseudomonas aeruginosa and other predictors
of mortality and morbidity in young children with cystic fibrosis.
Pediatr Pulmonol. 34(2):91-100.
6. Vanderhelst E, De Meirleir L,
Verbanck S, Piérard D, Vincken W, Malfroot A. 2012. Prevalence and
impact on fev1 decline of chronic methicillin-resistant staphylococcus
aureus (mrsa) colonization in patients with cystic fibrosis: A
single-center, case control study of 165 patients. Journal of Cystic
Fibrosis. 11(1):2-7.
7. Dasenbrook EC, Checkley W, Merlo
CA, Konstan MW, Lechtzin N, Boyle MP. 2010. Association between
respiratory tract methicillin-resistant staphylococcus aureus and
survival in cystic fibrosis. JAMA. 303(23):2386-2392.
8. Cystic fibrosis trust.
Recommendations – eradication and treatment of mrsa. In: Antibiotic
treatment for cystic
fibrosis. 3rd edn. Bromley, cystic fibrosis trust, 2009.
9. Mogayzel PJ, Jr., Naureckas ET,
Robinson KA, Brady C, Guill M, Lahiri T, Lubsch L, Matsui J, Oermann CM,
Ratjen F et al. 2014. Cystic fibrosis foundation pulmonary guideline.
Pharmacologic approaches to prevention and eradication of initial
pseudomonas aeruginosa infection. Ann Am Thorac Soc. 11(10):1640-1650.
10. Chmiel JF, Aksamit TR, Chotirmall
SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ,
Ratjen FA. 2014. Antibiotic management of lung infections in cystic
fibrosis. I. The microbiome, methicillin-resistant staphylococcus
aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac
Soc. 11(7):1120-1129.
11. Taccetti G, Bianchini E, Cariani
L, Buzzetti R, Costantini D, Trevisan F, Zavataro L, Campana S, Italian
Group for PaEiCF. 2012. Early antibiotic treatment for pseudomonas
aeruginosa eradication in patients with cystic fibrosis: A randomised
multicentre study comparing two different protocols. Thorax.
67(10):853-859.
12. Döring G, Flume P, Heijerman H,
Elborn JS. 2012. Treatment of lung infection in patients with cystic
fibrosis: Current and future strategies. J Cyst Fibros. 11(6):461-479.
13. Palser S, Smith S, Nash EF,
Agarwal A, Smyth AR. 2019. Treatments for preventing recurrence of
infection with pseudomonas aeruginosa in people with cystic fibrosis.
Cochrane Database Syst Rev. 12:CD012300.
14. Langton Hewer SC, Smyth AR. 2017.
Antibiotic strategies for eradicating pseudomonas aeruginosa in people
with cystic fibrosis. Cochrane Database of Systematic Reviews. (4).
15. Lo DK, Muhlebach MS, Smyth AR.
2018. Interventions for the eradication of meticillin-resistant
staphylococcus aureus (mrsa) in people with cystic fibrosis. Cochrane
Database Syst Rev. 7:CD009650.
16. Hewer SCL, Smyth AR, Brown M,
Jones AP, Hickey H, Kenna D, Ashby D, Thompson A, Williamson PR. 2020.
Intravenous versus oral antibiotics for eradication of pseudomonas
aeruginosa in cystic fibrosis (torpedo-cf): A randomised controlled
trial. Lancet Respir Med. 8(10):975-986.
17. Yohannes AM, Willgoss TG, Fatoye
FA, Dip MD, Webb K. 2012. Relationship between anxiety, depression, and
quality of life in adult patients with cystic fibrosis. Respir Care.
57(4):550-556.
18. Farrell PM, White TB, Ren CL,
Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M,
Rosenfeld M et al. 2017. Diagnosis of cystic fibrosis: Consensus
guidelines from the cystic fibrosis foundation. The Journal of
Pediatrics. 181:S4-S15.e11.
19. Lee TWR, Brownlee KG, Conway SP,
Denton M, Littlewood JM. 2003. Evaluation of a new definition for
chronic pseudomonas aeruginosa infection in cystic fibrosis patients.
Journal of Cystic Fibrosis. 2(1):29-34.
20. Doring G, Conway SP, Heijerman
HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. 2000. Antibiotic therapy
against pseudomonas aeruginosa in cystic fibrosis: A european consensus.
Eur Respir J. 16(4):749-767.
21. Vandekerckhove K, Keyzer M,
Cornette J, Coomans I, Pyl F, De Baets F, Schelstraete P, Haerynck F, De
Wolf D, Van Daele S et al. 2017. Exercise performance and quality of
life in children with cystic fibrosis and mildly impaired lung function:
Relation with antibiotic treatments and hospitalization. Eur J Pediatr.
176(12):1689-1696.
22. Akil N, Muhlebach MS. 2018.
Biology and management of methicillin resistant staphylococcus aureus in
cystic fibrosis. Pediatr Pulmonol. 53(S3):S64-S74.
23. Noah TL, Ivins SS, Abode KA,
Stewart PW, Michelson PH, Harris WT, Henry MM, Leigh MW. 2010. Inhaled
versus systemic antibiotics and airway inflammation in children with
cystic fibrosis and pseudomonas. Pediatr Pulmonol. 45(3):281-290.
24. Treggiari MM, Retsch-Bogart G,
Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P,
Gibson RL, Spencer T et al. 2011. Comparative efficacy and safety of 4
randomized regimens to treat early pseudomonas aeruginosa infection in
children with cystic fibrosis. Archives of Pediatrics & Adolescent
Medicine. 165(9):847-856.
25. Proesmans M, Vermeulen F,
Boulanger L, Verhaegen J, De Boeck K. 2013. Comparison of two treatment
regimens for eradication of pseudomonas aeruginosa infection in children
with cystic fibrosis. J Cyst Fibros. 12(1):29-34.
26. Poster session abstracts. 2016.
Pediatric Pulmonology. 51(S45):S194-S485.
27. Belarski E, Pettit R. 2020.
Outcomes of a methicillin-resistant staphylococcus aureus (mrsa)
eradication protocol in pediatric cystic fibrosis (cf) patients. Pediatr
Pulmonol. 55(3):654-659.
28. Doe SJ, McSorley A, Isalska B,
Kearns AM, Bright-Thomas R, Brennan AL, Webb AK, Jones AM. 2010. Patient
segregation and aggressive antibiotic eradication therapy can control
methicillin-resistant staphylococcus aureus at large cystic fibrosis
centres. J Cyst Fibros. 9(2):104-109.
29. Dolce D, Neri S, Grisotto L,
Campana S, Ravenni N, Miselli F, Camera E, Zavataro L, Braggion C,
Fiscarelli EV et al. 2019. Methicillin-resistant staphylococcus aureus
eradication in cystic fibrosis patients: A randomized multicenter study.
PLOS ONE. 14(3):e0213497.
30. Kappler M, Nagel F, Feilcke M,
Kroner C, Pawlita I, Naehrig S, Ripper J, Hengst M, von Both U, Forstner
M et al. 2016. Eradication of methicillin resistant staphylococcus
aureus detected for the first time in cystic fibrosis: A single center
observational study. Pediatr Pulmonol. 51(10):1010-1019.
31. Vallieres E, Rendall JC, Moore
JE, McCaughan J, Hoeritzauer AI, Tunney MM, Elborn JS, Downey DG. 2016.
Mrsa eradication of newly acquired lower respiratory tract infection in
cystic fibrosis. ERJ Open Res. 2(1).
32. Jackson L, Waters V. 2021.
Factors influencing the acquisition and eradication of early
<em>pseudomonas
aeruginosa</em> infection in cystic fibrosis.
Journal of Cystic Fibrosis. 20(1):8-16.
33. Rosenfeld M, Emerson J, McNamara
S, Thompson V, Ramsey BW, Morgan W, Gibson RL. 2012. Risk factors for
age at initial
<em>pseudomonas</em>
acquisition in the cystic fibrosis epic observational cohort. Journal of
Cystic Fibrosis. 11(5):446-453.
34. Dasenbrook EC, Merlo CA,
Diener-West M, Lechtzin N, Boyle MP. 2008. Persistent
methicillin-resistant staphylococcus aureus and rate of fev1 decline in
cystic fibrosis. Am J Respir Crit Care Med. 178(8):814-821.
35. Jennings MT, Dasenbrook EC,
Lechtzin N, Boyle MP, Merlo CA. 2017. Risk factors for persistent
methicillin-resistant staphylococcus aureus infection in cystic
fibrosis. J Cyst Fibros. 16(6):681-686.